Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida

被引:142
作者
Ahmad, Aijaz [1 ]
Khan, Amber [1 ]
Manzoor, Nikhat [1 ]
Khan, Luqman A. [1 ]
机构
[1] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India
关键词
Eugenol; Methyl eugenol; Fluconazole; Ergosterol; Candida; ANTIFUNGAL; RESISTANCE; ALBICANS; SUSCEPTIBILITY; MECHANISMS;
D O I
10.1016/j.micpath.2009.10.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Azoles target the ergosterol synthesizing enzyme lanosterol 14 alpha-demethylase and are a widely applied class of antifungal agents. Unfortunately azoles are generally fungistatic, and resistance to fluconazole is emerging in several fungal pathogens. In contrast to the increasing number of agents for the treatment of invasive fungal infections, discoveries of new antifungal agents with therapeutic value in dermatomycoses are reported only rare. Attention has been drawn to the antimicrobial activity of plants and their active principles due to the challenge of growing incidences of drug-resistant pathogens. Eugenol and methyl eugenol were reported to possess antimycotic properties. To further explore the antifungal activity of these compounds, in vitro studies were conducted on various Candida isolates. Insight studies to mechanism suggested that both eugenol and methyl eugenol exerts their antifungal activity by targeting sterol biosynthesis. Furthermore, it was also observed that additional methyl group to eugenol increases its antifungal activity. The observed fungicidal characteristics of both eugenol and methyl eugenol indicate that both the compounds might be promising antifungal agents defining a new class of antimycotics. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 30 条
[1]   Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness [J].
Anderson, JB .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (07) :547-556
[2]   Candida glabrata: In vitro susceptibility of 84 isolates to eight antifungal agents [J].
Arias, A ;
Arevalo, MP ;
Andreu, A ;
Rodriguez, C ;
Sierra, A .
CHEMOTHERAPY, 1996, 42 (02) :107-111
[3]  
Baris Ozlem, 2006, Turkish Journal of Biology, V30, P65
[4]   Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts [J].
Bastert, J ;
Schaller, M ;
Korting, HC ;
Evans, EGV .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (02) :81-91
[5]  
BETH A, 2000, ANTIMICROB AGENTS CH, V44, P2081
[6]   Systemic fungal infections in patients with hematologic malignancies:: Indications and limitations of the antifungal armamentarium [J].
Böhme, A ;
Karthaus, M .
CHEMOTHERAPY, 1999, 45 (05) :315-324
[7]   Calcineurin is essential for survival during membrane stress in Candida albicans [J].
Cruz, MC ;
Goldstein, AL ;
Blankenship, JR ;
Del Poeta, M ;
Davis, D ;
Cardenas, ME ;
Perfect, JR ;
McCusker, JH ;
Heitman, J .
EMBO JOURNAL, 2002, 21 (04) :546-559
[8]   The challenge of invasive fungal infection [J].
de Pauw, BE ;
Meunier, F .
CHEMOTHERAPY, 1999, 45 :1-14
[9]   Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis [J].
Fortun, J ;
LopezSanRoman, A ;
Velasco, JJ ;
SanchezSousa, A ;
deVicente, E ;
Nuno, J ;
Quereda, C ;
Barcena, R ;
Monge, G ;
Candela, A ;
Honrubia, A ;
Guerrero, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (04) :314-318
[10]  
FRANCOIS IE, 2000, CURR DRUG TARGETS, V6, P895